Sign in

Fatty liver disease (MASLD/MASH)

Current status: Treatable, not yet curable

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

Read more about fatty liver disease (MASLD/MASH)
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsAustralia, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with cirrhosis caused by fatty liver disease

    Tests efruxifermin against a placebo in adults with cirrhosis from MASH.

    Adelaide, AustraliaAlso Box Hill, Broadmeadow, Clayton, Coffs Harbour, Devonport, Epping, Heidelberg, Herston, …Age 18 to 80
  2. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver scarring from fatty liver disease

    Tests survodutide, a weekly injection, in adults with MASH cirrhosis.

    Clayton, AustraliaAlso Concord, Heidelberg, Kingswood, Liverpool, Parkville, Perth, WestmeadAge 18+
  3. Trial-stage treatmentPhase 1Taking people
    Tests INI-822 safety in healthy people and people with MASH liver disease

    Tests INI-822 against placebo in healthy adults and adults with MASH liver disease.

    Bedford Park, AustraliaAlso Birtinya, Box Hill, Campbelltown, Camperdown, Fitzroy, Mandurah, Newcastle, Osborne Park, …Age 18 to 70
  4. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with liver scarring from fatty liver disease

    Tests efruxifermin against a placebo in adults with fatty liver disease and mild liver scarring.

    Adelaide, AustraliaAlso Broadmeadow, Caulfield South, Coffs Harbour, Epping, Frankston, Heidelberg, Kogarah, Liverpool, …Age 18 to 80
  5. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver disease and moderate or advanced liver fibrosis

    Tests survodutide weekly injections against placebo in adults with fatty liver disease and scarring.

    Birtinya, AustraliaAlso Clayton, Concord, Heidelberg, Kingswood, Liverpool, Parkville, Perth, WestmeadAge 18+
  6. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin against placebo in liver scarring from fatty liver disease

    Tests pegozafermin doses versus placebo in adults with MASH and liver scarring.

    Adelaide, AustraliaAlso Bedford Park, Brisbane, Clayton, Fitzroy, Heidelberg, Herston, Murdoch, Perth, …Age 18 to 80
  7. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin in adults with liver scarring from fatty liver disease

    Tests pegozafermin against placebo in adults with compensated cirrhosis from MASH.

    Adelaide, AustraliaAlso Fitzroy, Greenslopes, Heidelberg, Herston, Murdoch, Perth, South BrisbaneAge 18 to 75
  8. Trial-stage treatmentPhase 3Taking people
    Tests retatrutide and tirzepatide in adults with fatty liver disease at high risk

    Tests retatrutide and tirzepatide in adults with fatty liver disease to prevent serious liver problems.

    Adelaide, AustraliaAlso Box Hill, Brisbane, Broadmeadow, Geelong, Heidelberg, Ipswich, Murdoch, Osborne Park, …Age 18+
  9. Trial-stage treatmentPhase 3Taking people
    Tests efimosfermin alfa injection in adults with fatty liver scarring

    Tests efimosfermin alfa injection for safety in adults with MASH liver disease.

    Woolloongabba, AustraliaAge 18 to 75
  10. Trial-stage treatmentPhase 3Taking people
    Tests efimosfermin alfa in adults with liver scarring from fatty liver disease

    Tests efimosfermin alfa against placebo in adults with MASH and moderate liver scarring.

    Broadmeadow, AustraliaAlso HeidelbergAge 18 to 75

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

These texts do not say it can be cured, but healthy lifestyle changes can reduce fat in the liver, help repair damage or stop it getting worse.

Recent EU-listed medicines are resmetirom (first EU approval August 2025) and semaglutide (March 2026), maybe first for another disease.

Approved: 2

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 18

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Support organisations

Patient organisations and helplines in Australia, for you and your family.

Fatty liver disease (MASLD/MASH) organisations in Australia

  • LiverWELL

    LiverWELL: Victorian liver health charity (incorporating Hepatitis Victoria) with a LiverLine, information on fatty liver disease (MASLD) and advocacy.

General support in Australia

  • Lifeline Australia

    Lifeline Australia: national charity providing all Australians with 24-hour crisis support and suicide prevention services.

  • healthdirect Australia

    healthdirect, the Australian Government-funded service providing trusted health information and advice online and by phone (1800 022 222).

Frontlight Community

Fatty liver disease (MASLD/MASH) community in Australia

People living with fatty liver disease (MASLD/MASH) and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

2 medicines are approved for fatty liver disease (MASLD/MASH) in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About fatty liver disease (MASLD/MASH)

Sources: NHS, MedlinePlus

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

What is it?

In this condition fat builds up in the liver. Its new name is MASLD (metabolic dysfunction-associated steatotic liver disease); it used to be called NAFLD. It is not caused by heavy drinking. There are four stages: fat alone (most people only have this and it does not usually cause problems); fat with inflammation (MASH, once called NASH); fibrosis (scarring); and cirrhosis, severe damage that affects how well the liver works.

It is very common: it is the most common long-term liver disease. It is more likely if you are overweight, especially around the waist, if you have type 2 diabetes, high blood pressure or high cholesterol, if you are not very active, or if you are over 50. Children can get it too. The exact cause is not known.

The first signs

Usually there are no signs, and it is often found during tests for something else.

  • feeling extremely tired;
  • feeling generally unwell;
  • discomfort or pain at the top right of the tummy, under the ribs.

How doctors find out

It is usually found after blood tests or scans done for another reason show signs of problems with your liver. Your family doctor asks about your symptoms and how much alcohol you drink, and measures your height, weight and waist. More blood tests and sometimes an ultrasound scan of your tummy can show the fat, rule out other causes and check for liver damage. If there is damage to your liver, you will need to see a liver specialist in hospital. Sometimes a biopsy is done to confirm the diagnosis and check for liver damage.

Current treatment

Lifestyle changes for everyone (healthy diet, at least 150 minutes of exercise a week, weight loss, little alcohol, no smoking), with pioglitazone or vitamin E from a specialist if there is scarring.

Will it get worse?

Most people only ever have the first stage, which usually causes no problems. A small number go on to inflammation and scarring, and some to cirrhosis, which can lead to bleeding inside the body, liver failure or liver cancer. It is also linked to heart disease, kidney disease, high blood pressure and type 2 diabetes. Healthy changes lower all these risks.

Medicines: what helps, and what to watch for

If there is scarring, a liver specialist may prescribe pioglitazone or vitamin E. For people with obesity, specialists may suggest weight-loss medicines. More research is needed to know which medicines are safe and work well.

Healthy changes help most

  • exercise for at least 150 minutes a week;
  • lose weight if you are overweight: it can reduce the fat, inflammation and scarring;

Weight-loss surgery or a transplant, for some people

For people with obesity, a specialist may recommend weight-loss surgery. In very severe cases, when the liver fails, a liver transplant may be needed.

Can it get better?

Healthy changes can reduce the fat in the liver and may repair damage or stop it getting worse. More studies are needed to see whether certain medicines are safe and work well to treat MASLD; studies are listed on ClinicalTrials.gov.

See the 426 trials you can join